CD44 and breast carcinoma: In 2003, Al-Hajj et al. published a groundbreaking work that breast cancer cells bearing the phenotype of CD44+/CD24− had enriched CSC properties, which set the foundation for studying CSCs in breast cancer and other solid tumors [18].